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number of people are affected every year 
by viral infections. In this regard, respira-
tory viral infections are the most common 
diseases identified in hospitalized chil-
dren.[1] Moreover, hepatitis, herpes, or 
human immunodeficiency infection 
(HIV) are also an important public con-
cern.[2–4] In fact, 325 million people world-
wide are affected by viral hepatitis leading 
to 1.34 million deaths annually,[5] and HIV 
is present in more than 36 million people, 
which means the death of 1 million people 
every year.[6] Another important public 
concern is the outbreak of new emerging 
viruses affecting human health. An 
example is SARS-CoV detected in 2002, 
and SARS-CoV-2 (COVID-19) which was 
first detected in 2019 in Wuhan, China, 
and spread worldwide.[7] RNA viruses, 
such as SARS-CoV or COVID-19, among 
others, have a high evolution (through 
mutation, reassortment, or recombina-
tion), allowing them a high adaptability 
to global changes, being able to generate local outbreaks up 
to pandemic worldwide.[8] In this regard, a clear example is 
H1N1 and H5N1 influenza A virus, which are defined by Jaijvan 
et  al.[8] as emergence and reemergence viruses. An important 
thing about this problem is regarding the atmospheric condi-
tions favoring virus diffusion. In this sense, Coccia[9] estab-
lished a clear high relation between the accelerated and vast 
diffusion of COVID-19 in North Italy and air pollution (elevated 
PM10 or ozone) and also low wind.
Other important concerns encompass are the emergence 
of resistance to the current antiviral therapies or cytotoxicity, 
The SARS-Cov-2 virus outbreak revealed that these nano-pathogens have 
the ability to rapidly change lives. Undoubtedly, SARS-Cov-2 as well as other 
viruses can cause important global impacts, affecting public health, as well 
as, socioeconomic development. But viruses are not only a public health 
concern, they are also a problem in agriculture. The current treatments are 
often ineffective, are prone to develop resistance, or cause considerable 
adverse side effects. The use of nanotechnology has played an important role 
to combat viral diseases. In this review three main aspects are in focus: first, 
the potential use of nanoparticles as carriers for drug delivery. Second, its 
use for treatments of some human viral diseases, and third, its application as 
antivirals in plants. With these three themes, the aim is to give to readers an 
overview of the progress in this promising area of biotechnology during the 
2017–2020 period, and to provide a glance at how tangible is the effectiveness 
of nanotechnology against viruses. Future prospects are also discussed. It is 
hoped that this review can be a contribution to general knowledge for both 
specialized and non-specialized readers, allowing a better knowledge of this 
interesting topic.
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1. Introduction
Viral infections have always proved to be a daring challenge to 
science and public health, due to their plasticity and their “hos-
tile takeover” of the metabolic machinery of the host cells. In 
fact, the virus dependence on the cell host metabolic machinery 
for their propagation greatly limits drug efficacy without non-
negligible cytotoxicity. Then, as well as other pathogenic micro-
organisms, damage caused by the viruses or “nano-pathogens” 
present a great concern for human and agricultural health 
worldwide. From a public health point of view, considerable 
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short plasma half-life, low solubility, among others.[10,11] 
Therefore, alternatives to traditional drug therapies are neces-
sary for the treatment of viral infections to overcome these 
barriers.
On the other hand, from an environmental health point 
of view, agricultural crops are also affected by viral diseases. 
Several viruses can infect important crop species resulting in 
significant economic losses.[12,13] Interestingly, more than two 
viruses can attack one crop at the same time.[14] An example 
is Geminiviridae family,[15] representing 360 species of plant 
viruses, and responsible for several diseases on economi-
cally important crops.[12,14] The main problem in field is that 
viruses reveal themselves normally via symptoms. The control 
is restricted to the vectors (insecticides), because the antivirals 
are scarce, and on many occasions ineffective.[14,16] Moreover, 
their inadequate use can represent a concerning level of envi-
ronmental pollution,[17] given that many chemical compounds 
used for the treatment of diseases in both public health and 
agricultural production can represent an environmental and 
health risk due to their active ingredient, at is shown by San-
Juan-Reyes et al.,[18] where clearly are indicated as persistent or 
toxic compounds commonly used such as quaternary ammo-
nium chloride, sodium hypochlorite, or orthophenylphenol 
(OPP).
Thermotherapy, crop rotation, or genetically resistant crops 
are also applied for virus control.[19,20] However, novel viral dis-
ease management in crops system that allows a more efficient 
control in field is warranted.
In relation to the aforementioned, the question arises why 
is it necessary the research of new source of technological 
solutions? What drives us to seek solutions for the treat-
ment of viral diseases in humans and in crops? The first, is 
that unsolved problems that cause human and economic 
losses are a constant concern. However, a relation between 
the development of technological trajectories, role to relevant 
problems as well as their solution to explain the emergence 
of path-breaking innovations and competitive advantage of 
firms, is shown.[21] About this, the nanotechnologies have been 
affecting biomedicine and agriculture with groundbreaking 
applications virology. In fact, several nanotechnological appli-
cations shown are effective strategies in diagnostics and treat-
ment (delivering antiviral drugs) of these pathologies[22,23] 
as shown in this manuscript. Moreover, nanotechnology has 
been supported by continuous growth in several areas such as 
genetics, genomics, proteomics among others.[22] An example 
of this is the recent advances in nanoparticle-based lateral flow 
immunoassays, which are used as easy, simple, rapid, and 
cost-effective tools, to be applied in pathogen detection in agri-
culture and medicine.[24]
Due to their size, exceptional properties and practical appli-
cations in many areas, nanoparticles and nanomaterials are a 
fascinating alternative to overcome the challenges caused by 
viral infections in both medicine and agriculture applications. 
But, why are nanoparticles so attractive to be used as an anti-
viral tool? Figure 1 describes the main mechanisms by which 
nanoparticles can exert their antiviral properties.[23] These 
outstanding properties have allowed developing of many new 
strategies in this “nano-war” against human and plant viruses. 
Undoubtedly, human health is a priority from every point 
of view. However, plants, crops in particular, are also vital to 
human health. In addition, viral diseases are difficult to treat, 
and lead to economic losses, due to poor-quality and lower yield 
production,[25] mainly affecting countries that depend on their 
agricultural production.
Therefore, this review provides an overview including some 
of the most recent reports (2017–2020) in which biotechnology 
has played an important role for public health and agriculture, 
for the progress in the treatment of viral diseases. We present 
the recent progress in the design and application of nanopar-
ticles as drug delivery carrier, and as a potential treatment for 
human and plant viral infections not only using texts but also 
with Figures and Tables. This review is aimed at both special-
ized and non-specialized readers interested in this spellbinding 
topic. When adequate, the reader will be referred to others with 
very interesting and specific reviews, for a more specialized 
lecture.
Figure 1. Main proposal mechanisms by which nanoparticles can exert their antiviral properties.[23]
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2. Nanoparticles as Nanocarriers for 
Antiviral drugs
Low bioavailability represents a major limitation for several 
antiviral drugs, which may occur due to their active excre-
tion or by exhibiting hydrophobicity and/or lipophobicity. 
Limited bioavailability usually depicts: reduced plasma half-
life, not achievable half-maximal inhibitory concentration 
(IC50), and a lower concentration threshold for drug crys-
tallization, which may cause a grievous acute renal failure. 
Acyclovir, zidovudine, efavirenz, cidofovir, tenofovir, lopi-
navir, among other antiviral drugs display low bioavailability. 
Moreover, antiviral drugs must be able to permeate through 
main body barriers to reach important virus reservoirs. This 
is particularly important for acquired immunodeficiency 
syndrome AIDS treatment since major human immunodefi-
ciency viruses (HIV) reservoirs are present in the brain, bone 
marrow, and adipose tissue.[26] Therefore, the development of 
nanocarriers for antiviral drugs has already proved to be effi-
cient in circumventing or minimizing the most relevant limi-
tations of antiviral drugs, particularly through their tailorable 
size. The main characteristics of each nanoparticle will influ-
ence the mechanisms involved in drug delivery.[27] However, 
their use as nanocarrier represents some advantages that are 
shown in Figure 2. Nanocarriers with an average size between 
200 and 30  nm have a higher potential to avoid immediate 
renal extraction and consequently to possess a higher plasma 
half-life. In addition, nanocarriers comprising a mean size 
ranging from 50 to 250  nm favorable to blood–brain bar-
rier permeation.[28] One of the most commonly and recently 
used nano solutions are the solid lipid nanoparticles (SLNPs) 
and poly (lactic-co-glycolic acid) nanoparticles (PLGANPs). 
SLNPs are able to carry a relevant quantity of lipophilic 
antiviral drugs in their lipid core, which is stabilized by a 
surfactant. Antiviral drug entrapment efficiency (EE) and 
loading capacity (LC) of SLNPs vary due to lipid and sur-
factant (and co-surfactant when present) composition, never-
theless the smaller size of SLNPs is indicated as a crucial to 
obtain higher EE and LC, due to the SLNPs higher surface 
area.[29–35] One of the most interesting PLGA-NPs property is 
their highly tailorable nature, with a considerable described 
methodology produce PLGANPs capable to carry lipophilic 
or hydrophilic molecules of different sizes and structural 
motifs, and assures its protection. In addition, PLGA-NPs 
surfaces are readily modifiable.[36–38] For instance, the func-
tionalization of PLGANPs with a maleimide-polyethylene 
Figure 2. The main advantages of nanoparticles as carrier antiviral drug delivery.
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glycol (PEG) improved plasma half-life by providing 
stealthiness towards reticuloendothelial system.[37] Valine 
functionalization of PLGA-PEG nanoparticles allowed its 
recognition by intestinal transporters improving the PLGA-
PEG-valine nanoparticles residence time and enhanced the 
permeability of carried acyclovir.[38] PLGANPs have also been 
used as a carrier for combined antiviral drugs, encompassing 
up to three different antiviral drugs, and a formulation 
showed viability to be applied subcutaneously, which may 
adapt to a wearable injector device, which would help prevent 
patient nonadherence.[39–41]
3. Human viral diseases and Nanoparticles
In the past 30 years, many antiviral agents have been formu-
lated as a possible therapy.[42,43] However, in some cases, these 
drugs are ineffective or they can cause critical side-effects.[44,45] 
Drug resistance has also been reported.[10,11] Therefore, new 
effective therapies are required. In the last ten years, nanopar-
ticles have emerged as an important tool to combat diseases.[46] 
Due to their interesting and unmatched properties, nanopar-
ticles can be used in different applications ranged from bio-
cides to nanocarriers for antiviral drugs. During the last ten 
years, many studies on viral diseases involving nanoparticles 
have been published, as reviewed by Sing et  al.[23] and Khez-
erlou et al.[47] Indeed, antiviral nano formulations (under evalu-
ation or clinically approved) are depicted by Singh et  al.[23] 
The next sections present different antiviral applications of 
nanoparticles.
3.1. Nanoparticles for viral Respiratory diseases
Viral respiratory pathologies have been a severe problem for 
public health, causing many deaths worldwide.[48,49] Indeed, 
pandemic influenza in 1918–1919 period caused more than 
25  million deaths,[50] and currently, COVID-19 pandemic led 
to more than 3 million infected people worldwide, and 216 000 
deaths until the end of April 2020.[51] Nanobiotechnology offers 
potential solutions for viral diseases, and some promissory 
results are summarized in Table 1.
Silver nanoparticles (AgNPs) have demonstrated antiviral 
activity.[53,61–63] SARS-CoV-2 virus is the most recent pandemic 
worldwide. Social mitigation strategies and non-specific drug 
therapies have been implemented.[64–69] Given that this is an 
emerging virus, studies involving nanoparticles are still scarce. 
However, Zachar et  al.[70] reported that inhalation delivery of 
AgNPs favored the response time of immune system. Poten-
tial action mechanisms of chloroquine on COVID-19 has been 
possible using synthetic nanoparticles.[71] In addition, Aydemir 
and Ulusu[72] reported that angiotensin-converting enzyme 2 
coated nanoparticles are an effective tool to be used in protec-
tive element to avoid the spread of the COVID-19.
Finally, given that no specific vaccines or drugs have been 
developed yet for the COVID-19 treatment, it is important to 
mention that nanotechnology has nevertheless offered a series 
of tools that can be used as biosensors for its detection. In this 
sense, gold,[73] lantanide-doped polystyrene,[74] or magnetic nan-
oparticles[75] and graphene[76] are presented as interesting nano-
structures to be used as biosensor for COVID-19 detection as 
reviewed by Srivastava et al.[77]
Table 1. Some recent examples of nanoparticles evaluated against respiratory viruses.
Virus or viral disease Nanoparticle Relevant Finding Reference
Influenza Virus AgNPs/ virus-inactivated flu vaccine Increase of immunoglobulin A and antibodies titers without 




AgNPs Increase in cherokine (CXCL1), granulocyte colony-stimulating 
and granulocyte-macrophage colony stimulating factors and 
decrease in pro-inflammatory cytokines and chemokines
[53]
H1N1 influence Fe3O4 50% in virus reduction after 72 h, and decrease in viral RNA 
transcripts (measured as antiviral activity).
[54]
phosphate nanoparticles As adjuvant in vaccine caused virus neutralization, high lgG 
antibodies, and higher inhibition of hemagglutination
[55]
PEG-coated ZnNp Viral inhibition rate > 90%, significant reduction in TCID50 
(Median Tissue Culture Infectious Dose)
[56]
H1N1, H3N2 and 
H5N1 virus
AuNp/M2e peptide Intranasal delivery in mice increased lung C cell activation 
and lgG1 and lgG2a subtypes. 100% protection for H1N1 and 
H5N1 and 92% for H3N2. Generated antibodies were binding 
to M2 expresses in infected cells.
[57]
H1N1 and H3N2 
virus
Two mixed nanoparticles as vaccine: a) protein 
matrix (M2c)/nucleoprotein antigens and 
b) M2c and papaya mosaic virus
Multimerization of nucleoprotein antigens on nanoparticles 
caused strong protection and significant immune response 
against the two viruses
[58]
H5N1, H1N1, H5N2, 
H7N3 and H9N2
Double-layered protein chitosan nanoparticle 
or cholera toxin subunit A1, matrix protein-2 
(sM2), fusion peptide of hemagglutinin 
(HA2), and poly-γ-glutamic acid-chitosan 
nanoparticles
High immunity against all viruses. [59,60]
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3.2. Nanoparticles for viral Skin diseases
AgNPs have demonstrated a high capacity for controlling 
herpes simplex virus types 1 and 2 (HSV-1 and HSV-2).[78] 
Results in mice showed that AgNPs modified with tannic acid, 
applied intravaginally, presented lower virus titers in the tissues, 
and a significant increase in the immune response.[79] Effective 
control of γ-herpesvirus-related cancer cell with AgNPs demon-
strated a higher cytotoxicity against infected cells with Kaposi’s 
sarcoma-associated herpesvirus (KSHV or HHV-8) or Epstein–
Barr Virus (EBV or HHV-4) through reactive oxygen species 
(ROS) generation and autophagy.[61] Biogenic AgNPs have also 
demonstrated antiviral effects against HSV virus, decreasing in 
more than 40% the cytopathic effect of HSV-1 and HSV-2.[80]
Sulfonated magnetic nanoparticles functionalized with gra-
phene oxide allowed an efficient capture of HSV-1, due to the 
higher photothermal antiviral activity (≈99.99%).[81] Studies in 
Vero-cells demonstrated a high effectivity of gold nanoparticles 
(AuNPs) against HSV-1 and HSV-2, preventing viral attachment 
and cell penetration.[82] AuNPs have the capacity to cross de 
blood–brain barrier in mice model, without cerebral damage, 
and inhibiting HSV-1 infection.[83] Interestingly, the authors 
reported that AuNPs also reduced HSV-1 induced β-secretase 
activity, which is related to Alzheimer’s disease.[84] Copper 
nanoparticles (CuNPs) at 100  µg mL−1 significantly decreased 
virus titers (HSV-1) with an inhibition rate of 83.3%.[85] In an 
interesting work, Lee et  al.[86] demonstrated that nanoparti-
cles modified with glycosaminoglycan attached to mesoporous 
silica nanoparticles, and loaded acyclovir, were efficient against 
HVS-1 and HVS-2, given that simultaneous target such as inhi-
bition of viral entry and inhibition of DNA replication occurred. 
Natural nanoparticles have also been demonstrated to be effi-
cient in the control of HSV-1. Shen et al.[87] reported that nano 
powder of Rheum tanguticum roots could interfere with the 
entire phase of viral replication of HSV-1 virus, inhibiting the 
infection through several mechanisms.
3.3. Nanoparticles for HIv-1 infection
Thousands of works have been reported on the use of nano-
particles as an emerging antiviral therapeutic agent in the war 
against HIV-1 (such as drug delivery carriers, vaccines coadju-
tant, among others). Therefore, we will give to the readers some 
examples in the recent progress of the uses of nanoparticles as 
antiviral agent or as carrier for drug delivery. For more detailed 
and specialized information, we recommend Gao et  al.,[88] 
Rezaeia et al.,[89] and Thalhauser et al.[90]
The mimic of the bind site of HIV-1 virus in CD4 T lympho-
cytes has been a strategy against HIV-1. The use of surface-
modified lactoferrin nanoparticles, conjugated with sodium 
2-mercaptoethanesulfonate, allows to mimic the bind site 
between HIV-1 viral protein gp120 and CCR5 (chemokine) and 
heparin sulfate (anionic polysaccharide) avoiding the infec-
tion.[91] Moreover, loading nanoparticles with antiretroviral 
agents allows a controlled release of high effective concentration 
of the drug in the infected zone. HIV-1 proteases (HIV-1 PR) 
are important and essential enzymes for the life-cycle of HIV-1. 
In this regard, AgNPs efficiently inhibited HIV-1 PR activity 
by specific bind to synthetic peptides with similar amino acid 
sequences to viral polyproteins.[92] The use of small interfering 
RNA (siRNA) has been evaluated to treat diseases as an impor-
tant strategy to regulate gene expression (RNA interference).[93] 
Chitosan nanoparticles modified with carboxymethyldextran 
or polyethylenimine were used as carrier delivery of anti-tat 
siRNA. These nanoparticles in mammalian cell line expressing 
HIV-1 Tat (transactivator of transcription) increased the cell via-
bility and anti-tat siRNA delivery efficiency. Moreover, RNA and 
protein expression of HIV-1 Tat was significantly reduced.[94] In 
the earliest stages of viral gene expression of HIV-1, an encoded 
important protein is Nef, which is critical in HIV-1 pathogen-
esis and considered a substantial virulence factor.[95,96] Carboxy-
methyl dextran-trimethyl chitosan-coated superparamagnetic 
iron oxide nanoparticles have shown to be an efficient carrier 
for delivery anti-nef siRNA, significantly reducing the expres-
sion of HIV-1 nef in cells.[96] Other HIV-1 inhibitors such as 
peptide (E2) (peptide derived from GB virus type C)[97] have 
been effectively loaded in polymeric nanoparticles covered with 
glycol-chitosan, and with effective mobility in vaginal mucus.[98] 
The envelope (Env) trimeric glycoprotein (GP) of HIV-1 is com-
posed of surface gp120 and transmembrane gp41 subunits 
organized as trimer of heterodimers, which has several mecha-
nisms to evade the host antibodies.[99] A widely studied strategy 
has been the immobilization of Env in a stable surface to be 
used as a potential vaccine. In this regard, Thalhauser et al.[100] 
reported the effective immobilization of an Env variant (BG505 
SOSIP.664) on a silica nanoparticle as a potential vaccine plat-
form, and it was demonstrated that Env variant showed struc-
tural integrity after their attachment. AuNPs have also been 
satisfactorily used as carrier of antiviral compounds. In this 
sense, AuNPs decorated with glycans were loaded with HIV-1 
peptides and mannosides-type oligosaccharides, and evaluated 
on dendritic cell (specialized antigen-presenting cells).[101] The 
results showed an increased proliferation of HIV-specific CD4 
and CD8 T cell, and a high secretion of functional cytokine due 
to functionalized AuNPs. Therefore, these strategies might be a 
promising approach to enhance vaccines against HIV-1.[101] Nev-
ertheless, further studies are required.
3.4. Nanoparticles for Hepatitis virus Infection
In recent years, several studies involving nanoparticles have 
reported satisfactory results for the control of HBV-A and 
HBV-B A potential vaccine based in alginate-coated chitosan 
nanoparticles (ACNp) loaded with hepatitis B surface anti-
bodies (HBsAg) and anchored with lipopolysaccharide, as adju-
vant for oral mucosal immunization, showed that HBsAg was 
protected by the nanoparticles, and it was detected that a sig-
nificant production of immunoglobulin A (sIgA) in mucosal, 
and IgG antibodies in blood circulation.[102] Similar results 
were reported by AbdelAllah et al.,[103] where ACNp was evalu-
ated as effective adjuvant for hepatitis A. Nanoparticle applica-
tion in mice showed production of interferon gamma (INF-γ), 
interleukin-10 (IL-10), and an increase in seroconversion rate 
(100%), splenocyte proliferation, and hepatitis A antibodies 
level. Given that HBV can cause hepatocellular injury, polypep-
tide penetratin-based hybrid nanoparticle system carrying IL-22 
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gene demonstrated that locally IL-22 protein (interleukin-22) 
expression and activation of STAT3 signaling pathway allowed 
to repair hepatocyte injury.[104] Local expression of IL-22 acti-
vated STAT3/Erk signal, inhibiting ROS accumulation, pro-
moting hepatocyte regeneration without side-effects in mice 
were observed. Wang et  al.[105] evaluated a vaccine in mice, 
which is based on ferritin nanoparticles and the delivery of 
the main hepatitis B antigen (pre S1) to specific myeloid cells, 
which are a critical arm of the immune system. The results 
demonstrated that high and persistent levels of anti-preS1 anti-
bodies were induced by the vaccine.
Advances in the treatment of hepatitis C (HCV) by using 
nanoparticles has also been reported. The subunit E1, an enve-
lope GP of hepatitis C virus, and sE2 (soluble E2) vaccine pro-
duced high neutralizing antibodies that can prevent HCV in 
mice.[106] To increase the sE2 immunogenicity, Yan et  al.[107] 
evaluated the fusion of sE2 (surface-displayed), ferritin unit in 
S2 cells (cell lines) self-assembled into a nanoparticle. Studies 
carrying out with mouse immunization revealed that the fusion 
of sE2-ferritin into nanoparticle was more efficient than sE2 in 
the induction of broadly neutralizing antibodies against HCV 
infection. Recently, He et  al.[108] developed a potential vaccine 
strategy for hepatitis C virus (HCV) treatment, redesigning 
E2 cores on ferritin nanoparticles. The authors reported that 
in mice a more effective neutralizing antibodies response was 
obtained with the use of the nanoparticles.
3.5. Nanoparticles for vector-Borne diseases
Vector-borne diseases are an important public health concern, 
some of them without a specific therapy, and the treatments 
are focused on symptomatic and supportive care.[109,110] Table 2 
summarizes some relevant findings obtained with nanoparti-
cles for vector-borne diseases.
4. Effects of Nanoparticles on 
viral Infections in Plants
Many viruses affect a wide range of crops and lead to huge 
losses in terms of economy and food supply. Recently, top 
10 scientifically and economically significant plant viruses 
were nominated considering 250 votes from the interna-
tional community.[120] The top 10 were ranked as follows: 
1) Tobacco mosaic virus (TMV), 2) Tomato spotted wilt virus, 
3) Tomato yellow leaf curl virus, 4) Cucumber mosaic virus, 
5) Potato virus Y, 6) Cauliflower mosaic virus, 7) African cas-
sava mosaic virus, 8) Plum pox virus, 9) Bromemosaic virus, 
and 10) Potato virus X.[120] As these viral infections may rep-
resent 15% loss of food supply, new strategies are inherent to 
prevent and treat, at least, the main affected crops.[121] The use 
of nanoparticles in agriculture has been increasing during 
the last few years. It is already well-known that at ideal con-
centrations, nanoparticles of different compositions are able 
to improve plants’ physiology, increasing plant growth, devel-
opment, and managing stress and bacterial, fungal, and viral 
infections.[122–124]
Nanoparticles can be applied through foliar or root appli-
cation, being able to penetrate cell wall and cell membrane, 
translocating to arterial parts and leaves.[125] The uptake is 
dependent on various factors such as soil, route exposure, and 
the intrinsic properties of nanoparticles (size, morphology, 
and surface features).[125] When plants are infected by virus, 
there is the accumulation of viral proteins in host cells, ena-
bling various roles of replication, movement, and suppres-
sion of host defense.[126] Nanoparticles are presented as an 
opportunity of combating viral infections in plants, owing to 
the ability of strong and direct interactions of the nanomate-
rials with viral surface GPs, enabling their access to the cells, 
interaction with the genoma and, blocking viral replication 
(Figure 3).
Table 2. Example of some relevant findings obtained with nanoparticles for vector-borne diseases.
Vector-borne disease Nanoparticles Relevant finding Reference
Chikungunya virus AgNPs Cell viability of infected cells increased 25% and 80% [111]
ZnONp Cell viability of infected cells increased 90% [112]
Zika virus Upconverting Gd2O3:Tb3+/Er3+ Humoral response in mice was enhanced [113]
SiNP functionalized with zwitterion and 
biological active group
Prevention of nonspecific protein adhesion and shielding  
effects against virus
[114]
Ebola virus Nickel nitrilotriacetic acid-functionalized lipid 
nanoparticles combined with rGP antigen
Virus neutralization by stimulated germinal center B cells and 
polyfunctional T cell
[115]
? EBOV GP nanoparticle vaccine with 
the saponin-based adjuvant Matrix-M 
(Novavax, Inc.)
Anti-EBOV GP immunoglobulin G titers were produced quickly in healthy 
adults. Assays with wild-type Zaire EBOV or pseudovirion were ninefold 
higher of Serum EBOV-neutralizing and binding antibodies
[116]
Dengue virus AuNPs/EDIII GP dengue virus High level of serotype-specific neutralization of dengue virus in BALB/c mice. [117]
PLGA nanoparticles/ tetravalent dengue virus 
protein subunit (rE)
High induction of neutralizing antibody, and a most balanced serotype 
specific antibody response to each dengue virus
[118]
Curcumin-based nano emulsion Improve solubility, cell uptake efficacy of curcumin, and 
dengue virus inhibition.
[119]
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4.1. Current Progress in the Administration of Nanoparticles 
against Plant viral Infection
Research englobing nanoparticles and agriculture has expo-
nentially grown in the last decade, evidenced by 25-fold more 
articles published in this area in 2019 when compared to 2011, 
as shown by Web of Science database. Even though, in gen-
eral, papers englobing the treatment of viral infections in crops 
using nanoparticles have not accompanied the general tendency 
of agricultural applications.[127] The application of nanoparticles 
against virus infection in plants is still unexplored and there 
is plenty of room to be studied.[128] Among the nanostructures, 
AgNPs have been the most studied against viral infections in 
different crops.
Table 3 summarizes the recent advances in the treatment of 
diverse plant viral infections with nanoparticles. AgNPs had 
already been reported as promising antiviral agent in general 
applications.[129] The antiviral potential of AgNPs has been dem-
onstrated against Sunhemp rosette virus-infected guar beans 
(Cymopsis tetragonaloba).[130] AgNPs (15 nm) synthesized with a 
spore crystal mixture of Bacillus thurigiensis were spray applied 
in contaminated leaves of guar beans in the concentration of 
50  mg L−1. After 3–4 days of inoculation of Sunhemp rosette 
virus, untreated plants demonstrated 100–150 lesions, while 
plants treated with AgNPs had no virus lesions, indicating that 
AgNPs led to complete suppression of the viral infection.[130] 
Similarly, AgNPs synthesized by Bacillus pumilus, Bacillus 
persicus, and Bacillus licheniformis led to 77–92 nm particles.[131] 
Bean yellow mosaic virus contaminated fava beans were treated 
with 0.1  µg µL−1 of AgNPs using two different strategies of 
application: i) administration of the nanoparticles 72 h prior 
to inoculation and ii) administration of the nanoparticles 24 h 
post-inoculation. Interestingly, the pre-treatment did not posi-
tively or negatively affect the viral infection, whereas the post-
treatment prevented all symptoms caused by the Bean yellow 
mosaic virus.[131]
Commercial or conventionally synthesized AgNPs also dem-
onstrated significative antiviral properties against Tomato mosaic 
virus, Tomato spotted wilt virus, and Potato virus Y.[132,133] Diver-
gent results were verified for tomato plants contaminated with 
both Tomato mosaic virus and Potato virus Y when compared 
to the ones contaminated with Bean yellow mosaic virus.[131,132] 
AgNPs at 50 ppm were spray applied 7 days before virus inocu-
lation, and the results showed that the disease severity was sig-
nificantly decreased for both viruses.[132] On the opposite, the 
treatment using AgNPs on potato plant infected with Tomato 
spotted wilt virus demonstrated that the best treatment condition 
was 24 h post virus inoculation.[132,133]
Other studies have been based on the use of metal oxide 
and carbon-based nanomaterials.[127,134] In vitro evaluation of 
biological effect of ZnO NPs (20  nm) and SiO2 NPs (18  nm) 
against Tobacco mosaic virus were performed and compared 
Figure 3. Schematic representation of nanoparticles uptake in plants and their interaction with viral hosts.
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to the effect of conventional agent letinan (LNT), currently 
used as antiviral agent.[134] Both ZnO NPs and SiO2 NPs led 
to more pronounced toxicity than the LNT. In vivo experi-
ments confirmed that the nanoparticles remarkably inhib-
ited virus replication, not only acting on plant defense but 
also increasing dry and fresh weights.[134] Hao and coworkers 
evaluated the potential of different nanomaterials against 
viral infection in Nicotiana benthamiana.[127] The plants were 
pre-treated with Fe2O3 or TiO2, and with multi-walled carbon 
nanotubes (MWCNT) or fullerene. Two different concentra-
tions (50 and 200  mg L−1) of each nanoparticle were foliar 
sprayed for 21 days prior to virus inoculation. All nanoparticles 
presented relative suppression of the viral infection, although 
results were more pronounced for MWCNT at 50 mg L−1.[127] 
Taha et al. demonstrated the potential of milk-proteins nano-
particles loaded with curcumin against Potato virus Y.[135] The 
nanoparticles were sprayed at different concentrations after 
7 and 14 days of infection. Results indicated a dose-dependent 
inhibition, reaching 100% at the highest evaluated concentra-
tion (1500 mg mL−1).[135]
This literature review reveals two major points: i) there 
is strong evidence of the positive effects that nanomate-
rials present in the treatment of virus infections in plants, 
and ii) the results are divergent and not standardized. From 
the highlighted papers, all were performed with a different 
type of virus and a different crop. Furthermore, the types of 
 nanoparticles employed were not only variated but also used 
in different concentrations and applied for different periods 
of time, pre- and post-virus inoculation. Thus, there is a 
strong need for standardization in the evaluation of the anti-
virus effects of nanoparticles in plants. The antivirus effects 
of nanoparticles in plants depend on: 1) virus type, 2) crop, 
3) nanoparticle composition, and 4) treatment protocol. Thus, 
further work should be developed to better understand the 
mechanisms and potential of different nanoparticles against 
a variety of viral infections in important crops, highlighting 
the ideal concentration ranges and the frequency/moment of 
application.
4.2. Unexplored Nanoparticles with Promising Potential against 
Crop viral Infection
Amongst different nanoparticles for agricultural applications, 
some examples should be highlighted as promisor candidates 
for future advances in viral infections management. A largely 
studied example is the use of chitosan nanoparticles (CS NPs). 
Recently, CS NPs have shown important effects in various 
fields of agriculture, such as pest management, fertilization, 
and improvement of plants in drought conditions.[136–138] Gen-
erally, the action of CS NPs in each application is intrinsically 
related to the content carried by those particles. The manage-
ment of pests was provided for CS NPs loaded with agrochemi-
cals or, alternatively, essential oils.[138,139] Montmorillonite clay 
and potassium nitrite loaded CS NPs were used for fertiliza-
tion, while drought tolerance was improved by nitric oxide (NO) 
loaded nanoparticles.[136,137] Similar strategies are also applied 
to other polymeric nanoparticles that act as capsules for con-
trolled release, such as acid-based PLGA-NPs which were used 
as carriers of antiviral ribavirin.[140] Results indicated that small 
nanoparticles (>100  nm) were successfully synthesized and 
that a sustained release of ribavirin, confirming the potential 
for future applications in the management of virus in crops.[140] 
Thus, the administration of polymeric nanoparticles represents 
a promising strategy for future studies regarding their applica-
tions in the control of viral infections in crops, through a con-
trolled and effective release of antiviral agents.
Metal and metal-oxide nanoparticles have also been vastly 
studied in the field of agriculture. Even representing the most 
studied nanoparticles against viral infections, there is still 
plenty of room to be explored in this regard. Species such as 
copper nanoparticles, cerium oxide, and zinc oxide nanoparti-
cles have already demonstrated promising applications in agri-
culture, however their effectiveness against viral infections, 
either by directly interacting with the virus or improving plants’ 
defense, have not been evaluated.[137,141,142] Different synthetic 
routes impact the size and surface properties of each nanopar-
ticle, reflecting nanoparticle adhesion, uptake pathways, and 
Table 3. Summary of relevant publications based on the use of nanoparticles against different viral infection in crops.
Virus Crop NPs composition NPs size Biological effect Ref




ZnO NPs  
and SiO2 NPs
55/62 nm Inactivation of TMV and 
inhibition of viral
[134]




AgNPs 20–100 nm NPs binded to virus coat protein 
and decreased virus concentration
[132]
Bean yellow  
mosaic virus
Vicia faba AgNPs 77–92 nm Decreased virus concentration 
and percentage of infection
[131]
Turnip mosaic  
virus
N. benthamiana Fe2O4, TiO2, carbon 
nanotubes, fullerene
40–100, 20, 30 
and 50 nm







AgNPs 15 nm Complete suppression of  
viral infection
[130]




AgNPs 12 nm Inhibitory effects were higher when NPs 
were sprayed after virus inoculation
[133]




235–335 nm Concentration-dependent virus 
inhibition
[135]
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translocation in plants.[143] Therefore, not only a larger variety of 
nanoparticles might be explored, but also the best parameters 
for each nanoparticle should be evidenced for specific applica-
tion, considering both crop and virus types.
5. No-Releasing Nanomaterials as a Promising 
Weapon against viral Infection in Plants
The gaseous free radical NO is found in plants and plays 
important functions in plant defense.[144] NO is produced in 
plants by an enzymatic pathway through the action of a NO 
synthase (NOS)-like enzyme and nitrite reductase.[145] As 
small and lipophilic molecule, NO easily diffuses across cell 
membranes acting as a biological messenger during various 
aspects of plant development and growth, such as senescence, 
photomorphogenesis, root growth leaf expansion, floral transi-
tion, stomatal closure, vegetative growth, cytokinin signaling, 
and programmed cell death.[145,146] NO is involved in the plant 
acclimation to different abiotic and biotic stresses including 
defense against pathogen attack.[147] Plant hormones such as 
salicylic acid, abscisic acid, auxin, jasmonic acid, cytokinin, and 
brassinosteroids enhance NO production during plant defense 
against microbial pathogens.[145,146] As a signaling molecule, NO 
mediates brassinosteroid resistance to Cucumber mosaic virus 
in Arabidopsis thaliana[148] and brassinosteroid cross talks with 
NO triggering the susceptibility of maize to chlorotic mottle 
virus infection.[147] NO and salicylic acid were reported to have 
a synergist effect against tomato mottle mosaic virus.[149] It has 
been reported that nitrate reductase (an enzyme that reduces 
nitrite to NO) alleviated cucumber mosaic virus in A. thaliana, 
in which synthesized NO regulated salicylic acid to mediate 
defense response.[150]
Exogenous administration of NO donors can trigger 
the expression of genes related to plant defense and thus 
increasing the generation of ROS inducing cell death. NO has 
been reported to be involved in the systemic acquired resist-
ance, conferring a broad-spectrum disease resistance to infec-
tions.[151] Moreover, NO can S-nitrosate cysteine thiol moieties 
of important biomolecules involved in the plant defense sign-
aling pathway.[152]
Recently, Lu et al reported the pretreatment of rice with the 
NO donor, sodium nitroprusside (100  µM), followed by infec-
tion with rice stripe virus.[153] The authors demonstrated that 
NO and melatonin play a key role in the virus-plant interaction 
in a synergistic manner. The administration of NO inhibitors 
or NO scavenger enhanced the incidence of rice stripe virus, 
confirming plant defense role of NO.[143]
Sodium nitroprusside associated with salicylic acid promoted 
plant (Arachis hypogaea L.) resistance against Peanut mottle 
virus infection. The plant resistance was accomplished by an 
increase in the photosynthetic pigments, an increase in the 
activity of antioxidant enzymes, a superior content of oils at the 
harvest time, and an increase in the levels of fatty acids, com-
pared with untreated plants.[154]
Therefore, NO plays a key role in plant defense against path-
ogens. Although the administration of NO donors has been 
extensively applied in biomedical applications, more recently 
in combination with nanomaterials,[155] this strategy is poorly 
explored in plant defense under biotic stress. NO donors and 
NO-releasing nanomaterials have been applied in the miti-
gation of plants under abiotic stresses, such as drought,[124] 
salinity,[156] UV-light exposure.[157] However, the administra-
tion of NO-releasing nanomaterials has not been extensively 
explored in plants under biotic stress. Due to the versatility 
and importance of NO in plant defense, further investigations 
should be explored in this promising topic.
6. Conclusion and Perspectives
The aim of this review is to provide information to the readers 
of the most current advances in the use of nanobiotechnology 
in the war against viruses, that is, application of nanoparticles 
for the control of viral infections. We have addressed the nano-
particles capacities as carrier of antiviral drugs, and the appli-
cations of these for human and plant viral pathologies. Recent 
progress has been demonstrated that nanoparticles allowed to 
overcome many challenges imposed through the use of conven-
tional antiviral therapies.[158] Nanoparticles allowed to overcome 
problems such as the cross of the blood barrier in the brain, 
and through their functionalization, to enhance the affinity of 
nanoparticle to the antiviral drugs, allowing a sustained and 
localized drug delivery. Depending on the chemical nature of 
the nanoparticle, the antiviral drug can be encapsulated in the 
nanoparticles or added to the nanoparticle surface. As stated in 
this review, the toxicity of antviral drugs can be decreased upon 
their loading in a nanoparticle (resulting in fewer side effects).
There are plenty of different nanoparticles that can be 
explored as antiviral carriers in mammals and in plants, 
ranging from biodegradable polymeric nanomaterials to rare 
earth upconverting nanoparticles. Depending on the nanopar-
ticle feature, not only antiviral drug release can be achieved, but 
also an enhanced interaction of the nanoparticle with the bio-
logical tissue, such as mucous tissue (in the case of mucosal 
delivery). In general, is known that bacterial activity is exer-
cised by small nanoparticles. However, antiviral activity has 
been demonstrated for most greater nanoparticles in quantum 
dots[159] and in small nanoparticles for AuNPs,[117] therefore 
size-dependent antiviral activity must be evaluated for each par-
ticular nanoparticle.
From the revised literature, it can be observed the emerging 
number of recent studies based on the potential of nanoparti-
cles for viral pathologies such as HIV, HVS -1, HSV-2, HBV-A, 
HBV-B, or influenza. However, studies involving nanoparticles 
and vector-borne viral diseases are scarce, even though they are 
a serious problem worldwide. According to reviewed literature, 
different nanoparticles doted of different elements such as anti-
bodies, drugs, siRNA, NO donors, among others, have demon-
strated a higher protection against viruses, acting as antiviral 
agent or in the promotion of the immune system defense. Still, 
additional clinical trials must be conducted.
In agriculture, the use the nanoparticles have gained con-
siderable attention in the last years. Nanoparticles of dif-
ferent composition improved plant physiology and growth, 
enhanced growth parameters under abiotic and biotic stress, 
including viral infections. The intrinsic properties of nano-
particles have allowed an efficient nanoparticle penetration 
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and translocation, and thus enhancing their antiviral effects 
in plants, in a similar manner to that in mammals. It should 
be noted that the antivirus effects can be assigned to the 
nanoparticle itself (such as in the case of AgNPs) or as a 
nanocarrier for antiviral agents (such as in the case of poly-
meric nanoparticles). Although several progresses have been 
reported in biomedical field, the use of nanoparticles for anti-
viral purposes in plants is still in its infancy, and more studies 
are required. Moreover, from the highlighted literature, it is 
clear that standardized methods are necessary for the evalua-
tion of antiviral activity in plants.
More studies involving unexplored biocompatible and biode-
gradable nanoparticles with potential against viral infections are 
required, such as chitosan nanoparticles or PLGA-NPs. Antimi-
crobial properties of copper, silver, cerium, or zinc oxides nano-
particles have been demonstrated. However, few studies have 
been carried out to evaluate their antiviral activity. Moreover, spe-
cific parameters (size, concentration, drug concentration, among 
others) associated with each nanoparticle should be evaluated con-
sidering the wide virus diversity as well as the crops. Finally, more 
studies involving NO-releasing nanoparticles in plant defense 
against virus are welcome, considering the key roles of NO in 
plant, as remarkedly demonstrated in biomedical applications.
Currently, large quantities of nanoparticles are being pro-
duced worldwide. From medical research studies, it is possible 
to affirm that many types of nanoparticles are being synthe-
sized every year, and that their safety and biocompatibility have 
been actively improving due to the rapid advance of nanobio-
technology. Undoubtedly, many gaps are still unsolved yet, but 
it is clear that nanobiotechnology in a short time might offer us 
many nano-tool alternatives to fight and win the battle against 
viral diseases in both, human and crop health.
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